Tag: Veterinary oncology

In a pivotal clinical trial, a single injection of Stelfonta led to complete tumor resolution in 75% of treated dogs within 28 days. What is Stelfonta? This injectable medication, also known as tigilanol tiglate, is a veterinary treatment option for certain non-metastatic mast cell tumors (MCTs) in dogs, offering a non-surgical alternative for hard-to-reach or difficult-to-excise tumors.

While the term 'MCT injection' might sound unfamiliar, it encompasses several distinct medical and veterinary applications, from using medium-chain triglycerides as a drug carrier for injectable hormones to a specific treatment for mast cell tumors in dogs. Understanding the context is crucial to determine what is an MCT injection, as the meaning is not universal across medicine.

According to research, mast cell tumors account for approximately 20% of all skin cancers in dogs, making them one of the most common malignancies in canines. The arrival of groundbreaking immunotherapies like **Gilvetmab** offers a new and promising approach to treating these tumors and other forms of canine cancer.